Skip to main content


Fig. 3 | Breast Cancer Research

Fig. 3

From: miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer

Fig. 3

The diagnostic accuracy and prognostic effect of miR-629-3p in patients with triple-negative breast cancer (TNBC) with lung metastasis. a In the training set, quantitative real-time polymerase chain reaction analysis of primary tumors indicated that the expression level of miR-629-3p in the lung metastasis group was significantly higher than in the recurrence-free group (P < 0.001). b ROC curve analysis demonstrated that miR-629-3p was a significant biomarker for diagnosis of lung metastasis, with an AUC of 0.865 (95% CI 0.800–0.930, P < 0.0001). c, d, and e High expression of miR-629-3p was correlated with a reduced overall survival (P < 0.001), disease-free survival (P = 0.002), and distant metastasis-free survival (P < 0.001) in univariate analysis. However, miR-629-3p failed to maintain a significant association after adjustment for confounding factors in multivariate analysis. f There was no difference in locoregional recurrence-free survival with respect to miR-629-3p expression (P = 0.116). miR MicroRNA

Back to article page